Tim Smith

The results of this analysis highlight the link between patients’ experiences with pruritus intensity and the mental health difficulties such struggles place on patients.

A post-AAD 2024 discussion on the importance of tailoring acne and rosacea management to individual patients’ needs, focusing more attention on diverse skin types and backgrounds.

In this AAD 2024 interview, Bunick highlights several new findings on the use of topical isotretinoin for treatment of congenital ichthyosis.

Alexis spoke in this AAD interview about his team’s results regarding lebrikizumab for adults and adolescents with moderate-to-severe atopic dermatitis and skin of color.

These data presented at AAD 2024 highlight deuruxolitinib’s efficacy in the treatment of adults with moderate-to-severe alopecia areata.

Another segment of Silverberg’s interview at AAD 2024 featured a discussion on safety data and the larger implications of these phase 3 findings for eczema management.

This interview at AAD featured a discussion with Silverberg on nemolizumab’s efficacy and safety at Week 48 among patients with moderate-to-severe atopic dermatitis.

These study findings, presented at AAD 2024, were the results of a recent analysis conducted to assess long-term outcomes among patients with psoriasis.

In this segment of his AAD interview, Hamzavi discussed more about his team’s findings on upadacitinib as well as their implications and future in terms of research.

In this interview segment, Lebwohl discusses the implications of his team’s late-breaking data on bimekizumab for clinical practice.

In this interview at AAD 2024, Porter discussed her team’s phase 2 findings on hidradenitis suppurativa the impact of ruxolitinib cream among those with Hurley Stage I and II.

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.

This AAD 2024 interview features a discussion with Lebwohl on his team’s new late-breaking data, covering long-term findings on bimekizumab.

These phase 3 findings from AAD 2024 suggest patients treated with baricitinib may continue to see scalp, eyelash, and eyebrow hair regrowth with specific dosing regimens.

In this interview at AAD 2024, Porter discusses recent data from the SUNSHINE and SUNRISE trials on secukinumab for patients with HS.

In late-breaking data from AAD 2024, treatment with the JNJ-2113 targeted oral peptide led to several notable findings regarding patients with moderate-to-severe psoriasis.

Hamzavi discusses new late-breaking data from AAD 2024, including major takeaways and safety profile after 52 weeks.

These findings from AAD 2024 did not include statistically significant infliximab response predictors, though it had been the largest reported cohort on the subject to date.

In this new analysis presented at AAD 2024, patients with HS saw substantial improvements in their hidradenitis suppurativa-related pain following treatment with bimekizumab.

A new analysis of the phase 3 ADORING 3 extension trial involved a large, diverse population and the analysis showed that 91% of eligible participants from previous phases rolled over into this trial.

In phase 4 data from the IMMpulse study, presented at AAD 2024, comparisons in efficacy were highlighted between risankizumab and apremilast for psoriasis patients eligible for systemic therapy.

In this discussion, Jonathan Silverberg described his team’s new phase 3 findings presented at AAD 2024 regarding upadacitinib and its impact on minimal disease activity in eczema patients.

These data suggest that, among children with atopic dermatitis and ADHD or other learning disabilities, an assessment for impairment of their cognitive abilities may need prioritization.

This analysis concluded that the carcinogen known as benzene can be broadly found in concerning levels within benzoyl peroxide (BPO) acne treatment products.

This analysis was conducted to address previous suspicions on the results of pulse oximetry among patients with skin of color.

These mental health outcomes were seen among those with self-reported COPD and asthma, though not among individuals with objective diagnoses based on spirometry.

This analysis looked into whether rapid respiratory virus testing in patients with suspected acute respiratory infection was linked to such outcomes as antibiotic use decrease and hospitalization.

This is the first instance in which a patient without a response to sequential bronchial thermoplasty, dupilumab, benralizumab, and mepolizumab ended up with a strong clinical response to tezepelumab.

This analysis explored views on safety, general levels of trust, and preferences on examination methods, with the goal being a greater awareness of opinion on AI incorporation.

These data suggest the potential for use of patient-reported outcomes in terms of risk stratification and selection of treatment for patients in both clinical practice and other studies.